285 related articles for article (PubMed ID: 22915662)
21. NICE guidance on rituximab for first-line treatment of symptomatic stage III-IV follicular lymphoma in previously untreated patients.
Doss S; Garrett Z; Sutcliffe F; Stevens A
Lancet Oncol; 2012 Feb; 13(2):128-30. PubMed ID: 22403811
[No Abstract] [Full Text] [Related]
22. Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS).
Wagner-Johnston ND; Link BK; Byrtek M; Dawson KL; Hainsworth J; Flowers CR; Friedberg JW; Bartlett NL
Blood; 2015 Aug; 126(7):851-7. PubMed ID: 26105149
[TBL] [Abstract][Full Text] [Related]
23. Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis.
Vidal L; Gafter-Gvili A; Salles G; Bousseta S; Oberman B; Rubin C; van Oers MH; Fortpied C; Ghielmini M; Pettengell R; Witzens-Harig M; Dreger P; Vitolo U; Gomes da Silva M; Evangelista A; Li H; Freedman L; Habermann TM; Shpilberg O
Eur J Cancer; 2017 May; 76():216-225. PubMed ID: 28336303
[TBL] [Abstract][Full Text] [Related]
24. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.
Salles G; Seymour JF; Offner F; López-Guillermo A; Belada D; Xerri L; Feugier P; Bouabdallah R; Catalano JV; Brice P; Caballero D; Haioun C; Pedersen LM; Delmer A; Simpson D; Leppa S; Soubeyran P; Hagenbeek A; Casasnovas O; Intragumtornchai T; Fermé C; da Silva MG; Sebban C; Lister A; Estell JA; Milone G; Sonet A; Mendila M; Coiffier B; Tilly H
Lancet; 2011 Jan; 377(9759):42-51. PubMed ID: 21176949
[TBL] [Abstract][Full Text] [Related]
25. Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 study.
Le Gouill S; De Guibert S; Planche L; Brice P; Dupuis J; Cartron G; Van Hoof A; Casasnovas O; Gyan E; Tilly H; Fruchart C; Deconinck E; Fitoussi O; Gastaud L; Delwail V; Gabarre J; Gressin R; Blanc M; Foussard C; Salles G;
Haematologica; 2011 Aug; 96(8):1128-35. PubMed ID: 21486862
[TBL] [Abstract][Full Text] [Related]
26. Outcome of patients with early-stage follicular lymphoma staged with
Ng SP; Khor R; Bressel M; MacManus M; Seymour JF; Hicks RJ; Wirth A
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):80-86. PubMed ID: 30083824
[TBL] [Abstract][Full Text] [Related]
27. Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era.
Nastoupil LJ; Sinha R; Byrtek M; Ziemiecki R; Zhou X; Taylor M; Friedberg JW; Link BK; Cerhan JR; Dawson K; Flowers CR
Br J Haematol; 2016 Mar; 172(5):724-34. PubMed ID: 26729445
[TBL] [Abstract][Full Text] [Related]
28. Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.
Ruella M; Filippi AR; Bruna R; Di Russo A; Magni M; Caracciolo D; Passera R; Matteucci P; Di Nicola M; Corradini P; Parvis G; Gini G; Olivieri A; Ladetto M; Ricardi U; Tarella C; Devizzi L
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):783-91. PubMed ID: 26972651
[TBL] [Abstract][Full Text] [Related]
29. Incidence of transformation to aggressive lymphoma in limited-stage follicular lymphoma treated with radiotherapy.
Bains P; Al Tourah A; Campbell BA; Pickles T; Gascoyne RD; Connors JM; Savage KJ
Ann Oncol; 2013 Feb; 24(2):428-432. PubMed ID: 23035152
[TBL] [Abstract][Full Text] [Related]
30. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
[TBL] [Abstract][Full Text] [Related]
31. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.
Morschhauser F; Radford J; Van Hoof A; Botto B; Rohatiner AZ; Salles G; Soubeyran P; Tilly H; Bischof-Delaloye A; van Putten WL; Kylstra JW; Hagenbeek A
J Clin Oncol; 2013 Jun; 31(16):1977-83. PubMed ID: 23547079
[TBL] [Abstract][Full Text] [Related]
32. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911
[TBL] [Abstract][Full Text] [Related]
33. [Effect of Rigorous Staging at the First Diagnosis on Prognosis of Patients with Follicular Lymphoma].
Wang L; Yan B; Yu Y; Wang YF; Yang HL; Zhao HF; Wang XF; Wu XX; DA WM; Li SX; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Feb; 25(1):126-132. PubMed ID: 28245388
[TBL] [Abstract][Full Text] [Related]
34. Fludarabine-mitoxantrone-rituximab regimen in untreated intermediate/high-risk follicular non-Hodgkin's lymphoma: experience on 142 patients.
Zinzani PL; Pellegrini C; Broccoli A; Casadei B; Argnani L; Pileri S
Am J Hematol; 2013 Nov; 88(11):E273-6. PubMed ID: 23843267
[TBL] [Abstract][Full Text] [Related]
35. Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma.
Luminari S; Ferrari A; Manni M; Dondi A; Chiarenza A; Merli F; Rusconi C; Tarantino V; Tucci A; Vitolo U; Kovalchuk S; Angelucci E; Pulsoni A; Arcaini L; Angrilli F; Gaidano G; Stelitano C; Bertoldero G; Cascavilla N; Salvi F; Ferreri AJM; Vallisa D; Marcheselli L; Federico M
J Clin Oncol; 2018 Mar; 36(7):689-696. PubMed ID: 29095677
[TBL] [Abstract][Full Text] [Related]
36. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
Coiffier B; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Walewski J; de Vos S; Crump M; Shpilberg O; Esseltine DL; Zhu E; Enny C; Theocharous P; van de Velde H; Elsayed YA; Zinzani PL;
Lancet Oncol; 2011 Aug; 12(8):773-84. PubMed ID: 21724462
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy with rituximab may be better than radiotherapy alone in first-line treatment of early-stage follicular lymphoma: is it time to change the standard strategy?
Janikova A; Bortlicek Z; Campr V; Kopalova N; Benesova K; Belada D; Prochazka V; Pytlik R; Vokurka S; Pirnos J; Duras J; Mocikova H; Mayer J; Trneny M
Leuk Lymphoma; 2015; 56(8):2350-6. PubMed ID: 25426666
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
[TBL] [Abstract][Full Text] [Related]
39. The long term follow-up of early stage follicular lymphoma treated with radiotherapy, chemotherapy or combined modality treatment.
Sancho JM; García O; Mercadal S; Pomares H; Fernández-Alvarez R; González-Barca E; Tapia G; González-García E; Moreno M; Domingo-Domènech E; Sorigué M; Navarro JT; Motlló C; Fernández-de-Sevilla A; Feliu E; Ribera JM
Leuk Res; 2015 Aug; 39(8):853-8. PubMed ID: 26122511
[TBL] [Abstract][Full Text] [Related]
40. Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis.
Prica A; Chan K; Cheung M
Cancer; 2015 Aug; 121(15):2637-45. PubMed ID: 25877511
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
